EVALUATION OF A LIVE ATTENUATED RECOMBINANT VIRUS RAV-9395 AS A HERPES-SIMPLEX VIRUS TYPE-2 VACCINE IN GUINEA-PIGS

Citation
Fc. Spector et al., EVALUATION OF A LIVE ATTENUATED RECOMBINANT VIRUS RAV-9395 AS A HERPES-SIMPLEX VIRUS TYPE-2 VACCINE IN GUINEA-PIGS, The Journal of infectious diseases, 177(5), 1998, pp. 1143-1154
Citations number
54
Categorie Soggetti
Infectious Diseases
ISSN journal
00221899
Volume
177
Issue
5
Year of publication
1998
Pages
1143 - 1154
Database
ISI
SICI code
0022-1899(1998)177:5<1143:EOALAR>2.0.ZU;2-0
Abstract
Recombinant virus RAV 9395 was constructed by deleting both copies of the gamma(1)34.5 gene, and the UL55 and UL56 open reading frames from herpes simplex virus type 2 (HSV-2) strain G. The potential use of RAV 9395 as an HSV-2 vaccine was investigated by evaluating the ability o f RAV 9395 to protect guinea pigs from severe disease by HSV-2(G) chal lenge. RAV 9395 administered intramuscularly reduced both lesion devel opment and severity in a dose dependent manner in guinea pigs challeng ed with HSV-Z(G). The frequency of reactivation of RAV 9395 from expla nted dorsal root ganglia was low compared with that of HSV-2(G). Immun ization with RAV 9395 at doses of 1 x 10(5) pfu and above generally pr ecluded the establishment of latency by the challenge virus. The resul ts presented in this report lend support for the development of geneti cally engineered live HSV vaccines.